首頁 > 市場調查報告書 > 醫療設備

體外診斷 POC診斷

POC (照護現場) 檢驗的全球市場 (2022-2030年):市場規模 (各產品、技術、處方、用途、終端用戶)、地區的展望、用途的潛在性、市場佔有率、預測

市場調查報告書

商品編碼

1100652

POC (照護現場) 檢驗的全球市場 (2022-2030年):市場規模 (各產品、技術、處方、用途、終端用戶)、地區的展望、用途的潛在性、市場佔有率、預測

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 - 2030

出版日期: 2022年07月06日 | 出版商:

Global Market Insights Inc. | 英文 430 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

POC (照護現場) 檢驗的市場，由於急性疾病患者增加，預計2030年大幅成長。近幾年，由於新型冠狀病毒感染疾病 (COVID-19) 的暴露風險在醫院的檢驗減少，POC檢驗的產品需求也提高。還有POC檢驗的重要優點的快速檢驗，在COVID-19大流行時帶來了正面的影響。

各產品中，血液檢驗產品的部門2021年顯示約38億9,170萬美元，預計2030年也取得大規模的利益。各技術中，分子診斷藥的部門在預測期間內預計記錄約8.0％的年複合成長率。

本報告提供全球POC (照護現場) 檢驗的市場調查，市場定義和概要，市場成長的各種影響因素分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

主要趨勢
血糖監測系統
- 帶
- 計器
- 採血針
心臟代謝檢驗產品
- 心臟標記檢驗產品
- 血氣/電解質檢驗產品
- HBA1C檢驗產品
傳染病檢查產品
- 流感檢驗產品
- HIV檢驗產品
- C型肝炎檢驗產品
- 性感染疾病(STD)檢驗產品
- 醫療相關感染(HAI)檢驗產品
- 呼吸系統傳染病檢查產品
- 熱帶病檢驗產品
- 其他的傳染病檢查產品
血液凝固檢驗產品
- PT/INR檢驗產品
- 活性化凝固時間(ACT/APTT)檢驗產品
妊娠及出生力檢驗產品
- 妊娠檢驗產品
- 出生力檢驗產品
腫瘤/癌症標記檢驗產品
膽固醇檢驗產品
血液檢驗產品
藥物濫用(DoA)檢驗產品
大便潛血試驗產品
尿液檢查產品
其他

第5章 POC (照護現場) 檢驗市場:各技術

主要趨勢
側向流動分析
沾棒
微流體
分子診斷
免疫學的檢驗
凝集化驗
流通
固相檢驗
生物感應器

第6章 POC (照護現場) 檢驗市場:各處方

主要趨勢
OTC檢驗
處方檢驗

第7章 POC (照護現場) 檢驗市場:各用途

主要趨勢
心臟代謝檢驗
傳染病檢查
腎臟檢驗
藥物濫用(DoA)檢驗
血糖值檢驗
妊娠檢驗
癌症生物標記檢驗
其他

第8章 POC (照護現場) 檢驗市場:各終端用戶

主要趨勢
醫院
診斷中心
研究實驗室
居家照護
其他

第9章 POC (照護現場) 檢驗市場:各地區

主要趨勢
北美
歐洲
亞太地區
南美
中東、非洲

第10章企業簡介

競爭儀表板
Abaxis
Abbott
Accubiotech Co, Ltd.
ACON Laboratories, Inc
Becton, Dickinson and Company
bioLytical Laboratories Inc
BioMrieux SA
Bio-Rad Laboratories, Inc
HemoCue AB(Danaher Corporation)
Dexcom, Inc
Dragerwerk Ag & Co
LifeScan IP Holdings, LLC
Medtronic plc
Meridian Bioscience, Inc
Nova Biomedical
OraSure Technologies, Inc
F. Hoffmann-La Roche
Siemens Healthineers AG
Sysmex Corporation
Trinity Biotech

簡介目錄

Product Code: 3086

The point of care testing market is expected to witness massive growth through 2030 owing to increasing number of patients with acute illnesses.

Recently, testing in hospitals saw a decline due to the risk of exposure to the novel coronavirus in these settings, which fueled product demand as point of care testing offers flexibility with regards to location. Additionally, rapid testing, a pivotal advantage of point of care assays, has also positively influenced market uptake during the COVID-19 pandemic.

Notably, surging research emphasis by industry players has been beneficial for the product landscape, which has enhanced overall market dynamics. For instance, in June 2022, LumiraDx, a UK-based diagnostics company reported that it had gained CE Mark for its product, the Amira Analyzer. This portable instrument is used for rapid COVID-19 testing.

The point of care testing market has been bifurcated on the basis of technology, application, product, prescription, end-use, and region.

On the basis of product, the market has been bifurcated into cardiometabolic testing products, coagulation testing products, tumor/cancer marker testing products, Drug-of-Abuse (DoA) testing products, cholesterol testing products, glucose monitoring, infectious disease testing products, pregnancy and fertility testing products, urinalysis testing products, hematology testing products, fecal occult testing products, and other products. Among these, the hematology testing products segment was valued at approximately $3,891.7 million in 2021 and is speculated to amass notable gains over 2022-2030.

In terms of technology, the point of care testing market has been segmented into dipsticks, molecular diagnostics, agglutination assays, solid phase, biosensors, flow-through, immunoassays, microfluidics, and lateral flow assays. The molecular diagnostics segment is expected to register a CAGR of around 8.0% over the analysis timeframe.

In context of prescription, the market has been divided into prescription-based testing and OTC testing. The prescription-based testing segment contributed to a market share of roughly 46.1% in 2021 and is estimated to exhibit solid growth in the upcoming time period.

Based on application, the point of care testing market has been divided into infectious disease testing, Drug-of-Abuse (DoA) testing, pregnancy testing, cardio metabolic testing, nephrology testing, blood glucose testing, cancer biomarker testing, and other applications. The infectious disease testing segment is set to witness steady growth, expanding at around 8.1% CAGR through the review period.

On the basis of end-use, the market has been divided into diagnostic centers, home-care settings, hospitals, research laboratories, and others. The research laboratories segment reached more than $4,111.8 million in revenue in 2021.

On the regional front, the point of care testing market in Latin America accounted for nearly 5.8% of the overall industry revenue in 2021. On the other hand, the Middle East & Africa point of care testing industry is set to experience robust growth at a CAGR of about 8.6% over the forecast period.

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data Sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Point of care testing industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 Technology trends
- 2.1.4 Prescription trends
- 2.1.5 Application trends
- 2.1.6 End-use trends
- 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Upward trend in disease prevalence among developing countries
  - 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
  - 3.3.1.3 Technological advancements
  - 3.3.1.4 Increasing R&D investment
  - 3.3.1.5 Growing geriatric population base globally
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Increasing R&D investment
  - 3.3.2.2 High cost of product development
3.4 Growth potential analysis
- 3.4.1 By product
- 3.4.2 By technology
- 3.4.3 By prescription
- 3.4.4 By application
- 3.4.5 By end-use
3.5 COVID-19 impact analysis
3.6 Pricing analysis, by cardiac markers, 2021
3.7 Regulatory landscape
3.8 Technology landscape
3.9 Company share analysis, 2021 (by region)
- 3.9.1 Global market share analysis, 2021
- 3.9.2 North America
- 3.9.3 Europe
- 3.9.4 Asia Pacific
- 3.9.5 Latin America
- 3.9.6 MEA
3.10 Porter's analysis
3.11 Competitive landscape, 2021
- 3.11.1 Company matrix analysis, 2021
3.12 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

4.1 Key segment trends
4.2 Glucose monitoring
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.2 Strips
  - 4.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.3 Meters
  - 4.2.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.4 Lancets
  - 4.2.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Cardiometabolic testing products
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.3.2 Cardiac marker testing products
  - 4.3.2.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.2 High sensitivity troponin I (hsTnI)
    - 4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.3 Brain natriuretic peptide (BNP)
    - 4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.4 D-dimer
    - 4.3.2.4.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.5 Creatine kinase-MB (CK-MB)
    - 4.3.2.5.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.6 Myoglobin
    - 4.3.2.6.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.7 Others
    - 4.3.2.7.1 Market size, by region, 2017-2030 (USD Million)
- 4.3.3 Blood Gas/Electrolytes testing products
  - 4.3.3.1 Market size, by region, 2017-2030 (USD Million)
- 4.3.4 HBA1C testing products
  - 4.3.4.1 Market size, by region, 2017-2030 (USD Million)
4.4 Infectious disease testing products
- 4.4.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.2 Influenza testing products
  - 4.4.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.3 HIV testing products
  - 4.4.3.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.4 Hepatitis C testing products
  - 4.4.4.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.5 Sexually transmitted disease (STD) testing products
  - 4.4.5.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.6 Healthcare-associated Infection (HAI) testing products
  - 4.4.6.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.7 Respiratory infection testing products
  - 4.4.7.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.8 Tropical disease testing products
  - 4.4.8.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.9 Other infectious diseases testing products
  - 4.4.9.1 Market size, by region, 2017-2030 (USD Million)
4.5 Coagulation testing products
- 4.5.1 Market size, by region, 2017-2030 (USD Million)
- 4.5.2 PT/INR testing products
  - 4.5.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.5.3 Activated clotting time (ACT/APTT) testing products
  - 4.5.3.1 Market size, by region, 2017-2030 (USD Million)
4.6 Pregnancy & fertility testing products
- 4.6.1 Market size, by region, 2017-2030 (USD Million)
- 4.6.2 Pregnancy testing products
  - 4.6.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.6.3 Fertility testing products
  - 4.6.3.1 Market size, by region, 2017-2030 (USD Million)
4.7 Tumor/Cancer marker testing products
- 4.7.1 Market size, by region, 2017-2030 (USD Million)
4.8 Cholesterol testing products
- 4.8.1 Market size, by region, 2017-2030 (USD Million)
4.9 Hematology testing products
- 4.9.1 Market size, by region, 2017-2030 (USD Million)
4.10 Drug-of-Abuse (DoA) testing products
- 4.10.1 Market size, by region, 2017-2030 (USD Million)
4.11 Fecal occult testing products
- 4.11.1 Market size, by region, 2017-2030 (USD Million)
4.12 Urinalysis testing products
- 4.12.1 Market size, by region, 2017-2030 (USD Million)
4.13 Other products
- 4.13.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

5.1 Key segment trends
5.2 Lateral flow assays
- 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Dipsticks
- 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
5.4 Microfluidics
- 5.4.1 Market size, by region, 2017 - 2030 (USD Million)
5.5 Molecular diagnostics
- 5.5.1 Market size, by region, 2017 - 2030 (USD Million)
5.6 Immunoassays
- 5.6.1 Market size, by region, 2017 - 2030 (USD Million)
5.7 Agglutination assays
- 5.7.1 Market size, by region, 2017 - 2030 (USD Million)
5.8 Flow-through
- 5.8.1 Market size, by region, 2017 - 2030 (USD Million)
5.9 Solid phase
- 5.9.1 Market size, by region, 2017 - 2030 (USD Million)
5.10 Biosensors
- 5.10.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

6.1 Key segment trends
6.2 OTC testing
- 6.2.1 Market size, by region, 2017 - 2030 (USD Million)
6.3 Prescription-based testing
- 6.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

7.1 Key segment trends
7.2 Cardio metabolic testing
- 7.2.1 Market size, by region, 2017 - 2030 (USD Million)
7.3 Infectious disease testing
- 7.3.1 Market size, by region, 2017 - 2030 (USD Million)
7.4 Nephrology testing
- 7.4.1 Market size, by region, 2017 - 2030 (USD Million)
7.5 Drug-of-Abuse (DoA) testing
- 7.5.1 Market size, by region, 2017 - 2030 (USD Million)
7.6 Blood glucose testing
- 7.6.1 Market size, by region, 2017 - 2030 (USD Million)
7.7 Pregnancy testing
- 7.7.1 Market size, by region, 2017 - 2030 (USD Million)
7.8 Cancer biomarker testing
- 7.8.1 Market size, by region, 2017 - 2030 (USD Million)
7.9 Other applications
- 7.9.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

8.1 Key segment trends
8.2 Hospitals
- 8.2.1 Market size, by region, 2017 - 2030 (USD Million)
8.3 Diagnostic centers
- 8.3.1 Market size, by region, 2017 - 2030 (USD Million)
8.4 Research laboratories
- 8.4.1 Market size, by region, 2017 - 2030 (USD Million)
8.5 Home-care settings
- 8.5.1 Market size, by region, 2017 - 2030 (USD Million)
8.6 other
- 8.6.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

9.1 Key regional trends
9.2 North America
- 9.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.2.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.2.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.2.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.2.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.2.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.2.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.2.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.2.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.2.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.2.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.2.7 U.S.
  - 9.2.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.2.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.2.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.2.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.2.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.2.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.2.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.2.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.2.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.2.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.2.8 Canada
  - 9.2.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.2.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.2.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.2.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.2.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.2.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.2.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.2.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.2.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.2.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.3 Europe
- 9.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.3.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.3.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.3.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.3.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.3.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.3.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.3.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.3.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.3.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.3.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.7 Germany
  - 9.3.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.8 UK
  - 9.3.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.9 France
  - 9.3.9.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.9.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.9.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.10 Spain
  - 9.3.10.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.10.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.10.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.11 Italy
  - 9.3.11.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.11.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.11.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.11.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.11.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.11.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.11.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.11.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.11.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.11.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.11.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.4 Asia Pacific
- 9.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.4.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.4.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.4.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.4.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.4.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.4.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.4.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.4.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.4.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.4.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.7 China
  - 9.4.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.8 India
  - 9.4.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.9 Japan
  - 9.4.9.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.9.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.9.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.10 Australia
  - 9.4.10.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.10.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.10.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.5 Latin America
- 9.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.5.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.5.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.5.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.5.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.5.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.5.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.5.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.5.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.5.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.5.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.5.7 Brazil
  - 9.5.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.5.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.5.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.5.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.5.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.5.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.5.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.5.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.5.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.5.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.5.8 Mexico
  - 9.5.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.5.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.5.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.5.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.5.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.5.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.5.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.5.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.5.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.5.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.6 MEA
- 9.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.6.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.6.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.6.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.6.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.6.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.6.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.6.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.6.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.6.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.6.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.6.7 South Africa
  - 9.6.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.6.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.6.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.6.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.6.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.6.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.6.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.6.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.6.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.6.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.6.8 Saudi Arabia
  - 9.6.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.6.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.6.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.6.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.6.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.6.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.6.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.6.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.6.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.6.8.5 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 10 Company Profiles

10.1 Competitive dashboard
10.2 Abaxis
- 10.2.1 Business overview
- 10.2.2 Financial data
- 10.2.3 Product landscape
- 10.2.4 Strategic outlook
- 10.2.5 SWOT analysis
10.3 Abbott
- 10.3.1 Business overview
- 10.3.2 Financial data
- 10.3.3 Product landscape
- 10.3.4 Strategic outlook
- 10.3.5 SWOT analysis
10.4 Accubiotech Co, Ltd.
- 10.4.1 Business overview
- 10.4.2 Financial data
- 10.4.3 Product landscape
- 10.4.4 Strategic outlook
- 10.4.5 SWOT analysis
10.5 ACON Laboratories, Inc
- 10.5.1 Business overview
- 10.5.2 Financial data
- 10.5.3 Product landscape
- 10.5.4 Strategic outlook
- 10.5.5 SWOT analysis
10.6 Becton, Dickinson and Company
- 10.6.1 Business overview
- 10.6.2 Financial data
- 10.6.3 Product landscape
- 10.6.4 Strategic outlook
- 10.6.5 SWOT analysis
10.7 bioLytical Laboratories Inc
- 10.7.1 Business overview
- 10.7.2 Financial data
- 10.7.3 Product landscape
- 10.7.4 Strategic outlook
- 10.7.5 SWOT analysis
10.8 BioMrieux SA
- 10.8.1 Business overview
- 10.8.2 Financial data
- 10.8.3 Product landscape
- 10.8.4 Strategic outlook
10.9 Bio-Rad Laboratories, Inc
- 10.9.1 Business overview
- 10.9.2 Financial data
- 10.9.3 Product landscape
- 10.9.4 Strategic outlook
- 10.9.5 SWOT analysis
10.10 HemoCue AB (Danaher Corporation)
- 10.10.1 Business overview
- 10.10.2 Financial data
- 10.10.3 Product landscape
- 10.10.4 Strategic outlook
- 10.10.5 SWOT analysis
10.11 Dexcom, Inc
- 10.11.1 Business overview
- 10.11.2 Financial data
- 10.11.3 Product landscape
- 10.11.4 Strategic outlook
- 10.11.5 SWOT analysis
10.12 Dragerwerk Ag & Co
- 10.12.1 Business overview
- 10.12.2 Financial data
- 10.12.3 Product landscape
- 10.12.4 Strategic outlook
- 10.12.5 SWOT analysis
10.13 LifeScan IP Holdings, LLC
- 10.13.1 Business overview
- 10.13.2 Financial data
- 10.13.3 Product landscape
- 10.13.4 Strategic outlook
- 10.13.5 SWOT analysis
10.14 Medtronic plc
- 10.14.1 Business overview
- 10.14.2 Financial data
- 10.14.3 Product landscape
- 10.14.4 Strategic outlook
- 10.14.5 SWOT analysis
10.15 Meridian Bioscience, Inc
- 10.15.1 Business overview
- 10.15.2 Financial data
- 10.15.3 Product landscape
- 10.15.4 Strategic outlook
- 10.15.5 SWOT analysis
10.16 Nova Biomedical
- 10.16.1 Business overview
- 10.16.2 Financial data
- 10.16.3 Product landscape
- 10.16.4 Strategic outlook
- 10.16.5 SWOT analysis
10.17 OraSure Technologies, Inc
- 10.17.1 Business overview
- 10.17.2 Financial data
- 10.17.3 Product landscape
- 10.17.4 Strategic outlook
- 10.17.5 SWOT analysis
10.18 F. Hoffmann-La Roche
- 10.18.1 Business overview
- 10.18.2 Financial data
- 10.18.3 Product landscape
- 10.18.4 Strategic outlook
- 10.18.5 SWOT analysis
10.19 Siemens Healthineers AG
- 10.19.1 Business overview
- 10.19.2 Financial data
- 10.19.3 Product landscape
- 10.19.4 Strategic outlook
- 10.19.5 SWOT analysis
10.20 Sysmex Corporation
- 10.20.1 Business overview
- 10.20.2 Financial data
- 10.20.3 Product landscape
- 10.20.4 Strategic outlook
- 10.20.5 SWOT analysis
10.21 Trinity Biotech
- 10.21.1 Business overview
- 10.21.2 Financial data
- 10.21.3 Product landscape
- 10.21.4 Strategic outlook
- 10.21.5 SWOT analysis